Follow
Viswa Colluru
Viswa Colluru
Enveda Therapeutics, Inc.
Verified email at envedatx.com - Homepage
Title
Cited by
Cited by
Year
Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells
CD Zahm, VT Colluru, DG McNeel
Cancer immunology research 5 (8), 630-641, 2017
592017
DNA vaccines for prostate cancer
CD Zahm, VT Colluru, DG McNeel
Pharmacology & therapeutics 174, 27-42, 2017
542017
Preclinical and clinical development of DNA vaccines for prostate cancer
VT Colluru, LE Johnson, BM Olson, DG McNeel
Urologic oncology: seminars and original investigations 34 (4), 193-204, 2016
482016
TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells
CD Zahm, VT Colluru, SJ McIlwain, IM Ong, DG McNeel
Cancer immunology research 6 (11), 1364-1374, 2018
452018
B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines
VT Colluru, DG McNeel
Oncotarget 7 (42), 67901, 2016
292016
Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses
VT Colluru, CD Zahm, DG McNeel
Oncoimmunology 5 (10), e1223002, 2016
242016
Vaccination with high-affinity epitopes impairs antitumor efficacy by increasing PD-1 expression on CD8+ T cells. Cancer Immunol. Res. 2017; 5: 630–641. doi: 10.1158/2326-6066
CD Zahm, VT Colluru, DG McNeel
CIR-16-0374, 0
13
Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand‐Binding Domain (AR‐LBD)
BM Olson, ES Bradley, T Sawicki, W Zhong, EA Ranheim, JE Bloom, ...
The Prostate 77 (7), 812-821, 2017
112017
TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8 (+) T Cells. Cancer Immunol. Res. 2018; 6: 1364–1374. doi: 10.1158/2326-6066
CD Zahm, VT Colluru, SJ McIlwain, IM Ong, DG McNeel
CIR-18-0243.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
8
In-silico characterization of ECE-1 inhibitors
PA Babu, VTSS Colluru, N Anaparthy
Computers in Biology and Medicine 42 (4), 446-457, 2012
52012
Targeting dna vaccines to b cells as primary antigen presenting cells
DG McNeel, VT Colluru
US Patent App. 17/191,378, 2021
22021
Targeting dna vaccines to b cells as primary antigen presenting cells
DG McNeel, VT Colluru
US Patent App. 14/935,095, 2016
22016
Abstract CN04-03: DNA vaccines as treatment for prostate cancer-understanding mechanisms of resistance
BT Rekoske, VT Colluru, DG McNeel
Molecular Cancer Therapeutics 14 (12_Supplement_2), CN04-03-CN04-03, 2015
12015
Immunization with minicircle and mini-intronic DNA vectors induce LAG-3 expressing CD8+ T cells and inferior anti-tumor responses
VT Colluru, DG McNeel
Cancer Research 75 (15_Supplement), 2502-2502, 2015
12015
B lymphocyte mediated antigen presentation of plasmid DNA
VT Colluru, DG McNeel
Journal for ImmunoTherapy of Cancer 1 (Suppl 1), 2013
12013
A Study on Refractive Errors of A Random Population Selected From Urban Areas of Visakhapatnam, India
VTSS Colluru, N Anaparthy, KR Sripathi, VR Kumari
12011
Targeting dna vaccines to b cells as primary antigen presenting cells
DG McNeel, VT Colluru
US Patent App. 16/278,415, 2019
2019
PI3-Kinase Inhibition and LAG-3 Checkpoint blockade as a Combination Therapy for Cancer
DG McNeel, VT Colluru, CD Zahm
US Patent App. 15/674,066, 2018
2018
Mini-intronic plasmid DNA vaccines in combination with LAG3 blockade
D McNeel, V Colluru
US Patent 9,827,308, 2017
2017
GP350 containing exosomes as DNA vaccine carriers
VT Colluru, DG McNeel
Cancer Research 76 (14_Supplement), 2360-2360, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–20